ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT

Fycompa 2 mg film-coated tablets  
Fycompa 4 mg film-coated tablets  
Fycompa 6 mg film-coated tablets  
Fycompa 8 mg film-coated tablets  
Fycompa 10 mg film-coated tablets  
Fycompa 12 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Fycompa 2 mg film-coated tablets

Each film-coated tablet contains 2 mg perampanel.  

Excipient with known effect: Each 2 mg tablet contains 78.5 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.

Fycompa 4 mg film-coated tablets

Each film-coated tablet contains 4 mg perampanel.  

Excipient with known effect: Each 4 mg tablet contains 157.0 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.

Fycompa 6 mg film-coated tablets

Each film-coated tablet contains 6 mg perampanel.  

Excipient with known effect: Each 6 mg tablet contains 151.0 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.

Fycompa 8 mg film-coated tablets

Each film-coated tablet contains 8 mg perampanel.  

Excipient with known effect: Each 8 mg tablet contains 149.0 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.

Fycompa 10 mg film-coated tablets

Each film-coated tablet contains 10 mg perampanel.  

Excipient with known effect: Each 10 mg tablet contains 147.0 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.

Fycompa 12 mg film-coated tablets

Each film-coated tablet contains 12 mg perampanel.  

Excipient with known effect: Each 12 mg tablet contains 145.0 mg of lactose (as monohydrate).  
For the full list of excipients, see section 6.1.
3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

**Fycompa 2 mg film-coated tablets**

Orange, round, biconvex tablet, engraved with E275 on one side and ‘2’ on other side

**Fycompa 4 mg film-coated tablets**

Red, round, biconvex tablet, engraved with E277 on one side and ‘4’ on other side

**Fycompa 6 mg film-coated tablets**

Pink, round, biconvex tablet, engraved with E294 on one side and ‘6’ on other side

**Fycompa 8 mg film-coated tablets**

Purple, round, biconvex tablet, engraved with E295 on one side and ‘8’ on other side

**Fycompa 10 mg film-coated tablets**

Green, round, biconvex tablet, engraved with E296 on one side and ‘10’ on other side

**Fycompa 12 mg film-coated tablets**

Blue, round, biconvex tablet, engraved with E297 on one side and ‘12’ on other side

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy (see section 5.1).

4.2 **Posology and method of administration**

**Posology**

*Adults and adolescents*

Fycompa must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability.

Perampanel should be taken orally once daily at bedtime.

*Partial-Onset Seizures*

Perampanel at doses of 4 mg/day to 12 mg/day has been shown to be effective therapy in partial-onset seizures.

Treatment with Fycompa should be initiated with a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day to 8 mg/day.

Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased by increments of 2 mg/day to 12 mg/day. Patients who are taking concomitant medicinal
products that do not shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 1-week intervals.

**Primary Generalised Tonic-Clonic Seizures**
Perampanel at a dose up to 8 mg/day has been shown to be effective in primary generalised tonic-clonic seizures.

Treatment with Fycompa should be initiated at a dose of 2 mg/day. The dose may be increased based on clinical response and tolerability by increments of 2 mg (either weekly or every 2 weeks, as per half-life considerations described below) to a maintenance dose of up to 8 mg/day. Depending upon individual clinical response and tolerability at a dose of 8 mg/day, the dose may be increased up to 12 mg/day, which may be effective in some patients (see section 4.4). Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 1-week intervals.

**Withdrawal**
It is recommended that discontinuation be undertaken gradually to minimise the potential for rebound seizures. However, due to its long half-life and subsequent slow decline in plasma concentrations, perampanel can be discontinued abruptly if absolutely needed.

**Missed doses**
Single missed dose: As perampanel has a long half-life, the patient should wait and take their next dose as scheduled.

If more than 1 dose has been missed, for a continuous period of less than 5 half-lives (3 weeks for patients not taking perampanel metabolism-inducing anti-epileptic drugs (AED), 1 week for patients taking perampanel metabolism-inducing AEDs (see section 4.5)), consideration should be given to re-start treatment from the last dose level.

If a patient has discontinued perampanel for a continuous period of more than 5 half-lives, it is recommended that initial dosing recommendations given above should be followed.

**Elderly (65 years of age and above)**
Clinical studies of Fycompa in epilepsy did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Analysis of safety information in 905 perampanel-treated elderly subjects (in double-blind studies conducted in non-epilepsy indications) revealed no age-related differences in the safety profile. In combination with the lack of age-related difference in perampanel exposure, the results indicate that dose-adjustment in the elderly is not required. Perampanel should be used with caution in elderly taking into account the drug interaction potential in polymedicated patients (see section 4.4).

**Renal impairment**
Dose adjustment is not required in patients with mild renal impairment. Use in patients with moderate or severe renal impairment or patients undergoing haemodialysis is not recommended.

**Hepatic impairment**
Dose increases in patients with mild and moderate hepatic impairment should be based on clinical response and tolerability. For patients with mild or moderate hepatic impairment, dosing can be initiated at 2 mg. Patients should be up-titrated using 2 mg doses no faster than every 2 weeks based on tolerability and effectiveness. Perampanel dosing for patients with mild and moderate impairment should not exceed 8 mg. Use in patients with severe hepatic impairment is not recommended.
Paediatric population
The safety and efficacy of perampanel in children below 12 years of age have not been established yet. No data are available.

Method of administration

Fycompa should be taken as single oral dose at bedtime. It may be taken with or without food (see section 5.2). The tablet should be swallowed whole with a glass of water. It should not be chewed, crushed or split. The tablets cannot be split accurately as there is no break line.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Suicidal ideation

Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for perampanel. Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.

Nervous system disorders

Perampanel may cause dizziness and somnolence and therefore may influence the ability to drive or use machines (see section 4.7).

Oral contraceptives

At doses of 12 mg/day Fycompa may decrease the effectiveness of progestative-containing hormonal contraceptives; in this circumstance additional non-hormonal forms of contraception are recommended when using Fycompa (see section 4.5).

Falls

There appears to be an increased risk of falls, particularly in the elderly; the underlying reason is unclear.

Aggression

Aggressive and hostile behaviour has been reported in patients receiving perampanel therapy. In perampanel-treated patients in clinical trials, aggression, anger and irritability were reported more frequently at higher doses. Most of the reported events were either mild or moderate and patients recovered either spontaneously or with dose adjustment. However, thoughts of harming others, physical assault or threatening behaviour were observed in some patients (<1% in perampanel clinical studies). Patients and caregivers should be counselled to alert a healthcare professional immediately if significant changes in mood or patterns of behaviour are noted. The dosage of perampanel should be reduced if such symptoms occur and should be discontinued immediately if symptoms are severe.
Abuse potential

Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of perampanel abuse.

Concomitant CYP 3A inducing anti-epileptic medicinal products

Response rates after addition of perampanel at fixed doses were less when patients received concomitant CYP3A enzyme-inducing anti-epileptic medicinal products (carbamazepine, phenytoin, oxcarbazepine) as compared to response rates in patient who received concomitant non-enzyme-inducing anti-epileptic medicinal products. Patients’ response should be monitored when they are switching from concomitant non-inducer anti-epileptic medicinal products to enzyme inducing medicinal products and vice versa. Depending upon individual clinical response and tolerability, the dose may be increased or decreased 2 mg at a time (see section 4.2).

Other concomitant (non- anti-epileptic) cytochrome P450 inducing or inhibiting medicinal products

Patients should be closely monitored for tolerability and clinical response when adding or removing cytochrome P450 inducers or inhibitors, since perampanel plasma levels can be decreased or increased; the dose of perampanel may need to be adjusted accordingly.

Fycompa contains lactose, therefore patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Fycompa is not considered a strong inducer or inhibitor of cytochrome P450 or UGT enzymes (see section 5.2).

Oral contraceptives

In healthy women receiving 12 mg (but not 4 or 8 mg/day) for 21 days concomitantly with a combined oral contraceptive, Fycompa was shown to decrease the levonorgestrel exposure (mean \(C_{\text{max}}\) and AUC values were each decreased by 40%). Ethinylestradiol AUC was not affected by Fycompa 12 mg whereas \(C_{\text{max}}\) was decreased by 18%. Therefore, the possibility of decreased efficacy of progestative-containing oral contraceptives should be considered for women needing Fycompa 12 mg/day and an additional reliable method (intra-uterine device (IUD), condom) is to be used (see section 4.4).

Interactions between Fycompa and other anti-epileptic medicinal products

Potential interactions between Fycompa (up to 12 mg once daily) and other anti-epileptic drugs (AEDs) were assessed in clinical studies and evaluated in the population PK analysis of four pooled Phase 3 studies including patients with partial-onset seizures and primary generalised tonic-clonic seizures. The effect of these interactions on average steady state concentration is summarised in the following table.
<table>
<thead>
<tr>
<th>AED coadministered</th>
<th>Influence of AED on Fycompa concentration</th>
<th>Influence of Fycompa on AED concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>2.75 fold decrease</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Clobazam</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>1.9 fold decrease</td>
<td>35% increase 1)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>1.7 fold decrease</td>
<td>No influence</td>
</tr>
<tr>
<td>Topiramate</td>
<td>19% decrease</td>
<td>No influence</td>
</tr>
<tr>
<td>Valproic Acid</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>No influence</td>
<td>No influence</td>
</tr>
</tbody>
</table>

1) Active metabolite monohydroxycarbazepine was not assessed.

Some anti-epileptic drugs known as CYP450 3A enzyme inducers (carbamazepine, phenytoin, oxcarbazepine) have been shown to increase perampanel clearance and consequently to decrease plasma concentrations of perampanel. Conversely, withdrawal of a concomitant CYP450 3A enzyme inducer can be expected to increase plasma concentrations of perampanel and dose reduction may be required.

Carbamazepine, a known potent enzyme inducer, reduced perampanel levels by two-thirds in a study performed on healthy subjects.

A similar result was seen in a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials. The total clearance of Fycompa was increased when administered with carbamazepine (2.75-fold), phenytoin (1.7-fold) and oxcarbazepine (1.9-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be taken into account and managed when adding or withdrawing these anti-epileptic drugs from a patient’s treatment regimen.

In a population pharmacokinetic analysis of patients with partial-onset seizures receiving Fycompa up to 12 mg/day in placebo-controlled clinical trials, Fycompa did not affect to a clinically relevant manner the clearance of clonazepam, levetiracetam, phenobarbital, phenytoin, topiramate, zonisamide, carbamazepine, clobazam, lamotrigine and valproic acid, at the highest perampanel dose evaluated (12 mg/day).

In the epilepsy population pharmacokinetic analysis, perampanel was found to decrease the clearance of oxcarbazepine by 26%. Oxcarbazepine is rapidly metabolised by cytosolic reductase enzyme to the active metabolite, monohydroxycarbazepine. The effect of perampanel on monohydroxycarbazepine concentrations is not known.

Perampanel is dosed to clinical effect regardless of other AEDs.

**Effect of perampanel on CYP3A substrates**

In healthy subjects, Fycompa (6 mg once daily for 20 days) decreased midazolam AUC by 13%. A larger decrease in exposure of midazolam (or other sensitive CYP3A substrates) at higher Fycompa doses cannot be excluded.

**Effect of cytochrome P450 inducers on perampanel pharmacokinetics**

Strong inducers of cytochrome P450, such as rifampicin and hypericum, are expected to decrease perampanel concentrations and the potential for higher plasma concentrations of reactive metabolites.
in their presence has not been excluded. Felbamate has been shown to decrease the concentrations of some medicinal products and may also reduce perampanel concentrations.

**Effect of cytochrome P450 inhibitors on perampanel pharmacokinetics**

In healthy subjects, the CYP3A4 inhibitor ketoconazole (400 mg once daily for 10 days) increased perampanel AUC by 20% and prolonged perampanel half-life by 15% (67.8 h vs 58.4 h). Larger effects cannot be excluded when perampanel is combined with a CYP3A inhibitor with longer half-life than ketoconazole or when the inhibitor is given for a longer treatment duration.

*Levodopa*

In healthy subjects, Fycompa (4 mg once daily for 19 days) had no effect on $C_{\text{max}}$ or AUC of levodopa.

**Alcohol**

The effects of perampanel on tasks involving alertness and vigilance such as driving ability were additive or supra-additive to the effects of alcohol itself, as found in a pharmacodynamic interaction study in healthy subjects. Multiple dosing of perampanel 12 mg/day increased levels of anger, confusion, and depression as assessed using the Profile of Mood State 5-point rating scale (see section 5.1). These effects may also be seen when Fycompa is used in combination with other central nervous system (CNS) depressants.

**Paediatric population**

Interaction studies have only been performed in adults.

In a population pharmacokinetic analysis of the adolescent patients in the Phase 3 clinical studies, there were no notable differences between this population and the overall population.

4.6 **Fertility, pregnancy and lactation**

**Women of childbearing potential and contraception in males and females**

Fycompa is not recommended in women of childbearing potential not using contraception unless clearly necessary.

**Pregnancy**

There are limited amounts of data (less than 300 pregnancy outcomes) from the use of perampanel in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats at maternally toxic doses (see section 5.3). Fycompa is not recommended during pregnancy.

**Breast-feeding**

Studies in lactating rats have shown excretion of perampanel and/or its metabolites in milk (for details see section 5.3). It is not known whether perampanel is excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

**Fertility**

In the fertility study in rats, prolonged and irregular oestrous cycles were observed at high-dose (30 mg/kg) in females; however, these changes did not affect the fertility and early embryonic development. There were no effects on male fertility (see section 5.3). The effect of perampanel on human fertility has not been established.
4.7 Effects on ability to drive and use machines

Fycompa has moderate influence on the ability to drive and use machines. Perampanel may cause dizziness and somnolence and, therefore, may influence the ability to drive or use machines. Patients are advised not to drive a vehicle, operate complex machinery or engage in other potentially hazardous activities until it is known whether perampanel affects their ability to perform these tasks (see sections 4.4 and 4.5).

4.8 Undesirable effects

Summary of the safety profile

In all controlled and uncontrolled trials in patients with partial-onset seizures, 1,639 subjects have received perampanel of whom 1,147 have been treated for 6 months and 703 for longer than 12 months.

In the controlled and uncontrolled trial in patients with primary generalised tonic-clonic seizures, 114 subjects have received perampanel of whom 68 have been treated for 6 months and 36 for longer than 12 months.

Adverse reactions leading to discontinuation:
In the controlled Phase 3 partial-onset seizures clinical trials, the rate of discontinuation as a result of an adverse reaction was 1.7%, 4.2% and 13.7% in patients randomised to receive perampanel at the recommended doses of 4 mg, 8 mg and 12 mg/day, respectively, and 1.4% in patients randomised to receive placebo. The adverse reactions most commonly (≥ 1% in the total perampanel group and greater than placebo) leading to discontinuation were dizziness and somnolence.

In the controlled Phase 3 primary generalised tonic-clonic seizures clinical trial, the rate of discontinuation as a result of an adverse reaction was 4.9% in patients randomised to receive perampanel 8 mg, and 1.2% in patients randomised to receive placebo. The adverse reaction most commonly leading to discontinuation (≥ 2% in the perampanel group and greater than placebo) was dizziness.

Tabulated list of adverse reactions

In the table below, adverse reactions, which were identified based on review of the full Fycompa clinical studies safety database, are listed by System Organ Class and frequency. The following convention has been used for the classification of adverse reactions: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100).

Within each frequency category, adverse reactions are presented in order of decreasing seriousness.
<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism and nutrition disorders</td>
<td></td>
<td>Decreased appetite</td>
<td>Increased appetite</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td>Aggression</td>
<td>Suicidal ideation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anger</td>
<td>Suicide attempt</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anxiety</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Confusional state</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dizziness</td>
<td>Ataxia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Dysarthria</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Balance disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irritability</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td>Diplopia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vision blurred</td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td>Vertigo</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td>Back pain</td>
<td></td>
</tr>
<tr>
<td>General disorders</td>
<td></td>
<td>Gait disturbance</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fatigue</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td>Weight increased</td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td></td>
<td>Fall</td>
<td></td>
</tr>
</tbody>
</table>

**Paediatric population**

Based on the clinical trial database of 196 adolescents exposed to perampanel from double-blind studies for partial-onset seizures and primary generalised tonic-clonic seizures, the overall safety profile in adolescents was similar to that of adults, except for aggression, which was observed more frequently in adolescents than in adults.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

There is limited clinical experience with perampanel overdose in humans. In a report of an intentional overdose that could have resulted in a dose up to 264 mg, the patient experienced events of altered mental status, agitation and aggressive behaviour and recovered without sequelae. There is no available specific antidote to the effects of perampanel. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. In view of its long half-life, the effects caused by perampanel could be prolonged. Because of low renal clearance special interventions such as forced diuresis, dialysis or haemoperfusion are unlikely to be of value.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX22
Mechanism of action

Perampanel is a first-in-class selective, non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons. Glutamate is the primary excitatory neurotransmitter in the central nervous system and is implicated in a number of neurological disorders caused by neuronal overexcitation. Activation of AMPA receptors by glutamate is thought to be responsible for most fast excitatory synaptic transmission in the brain. In in vitro studies, perampanel did not compete with AMPA for binding to the AMPA receptor, but perampanel binding was displaced by noncompetitive AMPA receptor antagonists, indicating that perampanel is a noncompetitive AMPA receptor antagonist. In vitro, perampanel inhibited AMPA-induced (but not NMDA-induced) increase in intracellular calcium. In vivo, perampanel significantly prolonged seizure latency in an AMPA-induced seizure model.

The precise mechanism by which perampanel exerts its antiepileptic effects in humans remains to be fully elucidated.

Pharmacodynamic effects

A pharmacokinetic-pharmacodynamic (efficacy) analysis was performed based on the pooled data from the 3 efficacy trials for partial-onset seizures. In addition, a pharmacokinetic-pharmacodynamic (efficacy) analysis was performed in one efficacy trial for primary generalised tonic-clonic seizures. In both analyses, perampanel exposure is correlated with reduction in seizure frequency.

Psychomotor performance

Single and multiple doses of 8 mg and 12 mg impaired psychomotor performance in healthy volunteers in a dose-related manner. The effects of perampanel on complex tasks such as driving ability were additive or supra-additive to the impairment effects of alcohol. Psychomotor performance testing returned to baseline within 2 weeks of cessation of perampanel dosing.

Cognitive function

In a healthy volunteer study to assess the effects of perampanel on alertness, and memory using a standard battery of assessments, no effects of perampanel were found following single and multiple doses of perampanel up to 12 mg/day.

In a placebo controlled study conducted in adolescent patients, no significant changes in cognition relative to placebo as measured by Cognitive Drug Research (CDR) System Global Cognition Score were observed for perampanel. In the open label extension, no significant changes were observed in global CDR system score after 52 weeks of perampanel treatment (see section 5.1 Paediatric population).

Alertness and mood

Levels of alertness (arousal) decreased in a dose-related manner in healthy subjects dosed with perampanel from 4 to 12 mg/day. Mood deteriorated following dosing of 12 mg/day only; the changes in mood were small and reflected a general lowering of alertness. Multiple dosing of perampanel 12 mg/day also enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion and depression as assessed using the Profile of Mood State 5-point rating scale.

Cardiac electrophysiology

Perampanel did not prolong the QTc interval when administered in daily doses up to 12 mg/day, and did not have a dose-related or clinically important effect on QRS duration.

Clinical efficacy and safety

Partial-Onset Seizures

The efficacy of perampanel in partial-onset seizures was established in three adjunctive therapy 19 week, randomised, double-blind, placebo-controlled, multicentre trials in adult and adolescent
patients. Subjects had partial-onset seizures with or without secondary generalisation and were not adequately controlled with one to three concomitant AEDs. During a 6-week baseline period, subjects were required to have more than five seizures with no seizure-free period exceeding 25 days. In these three trials, subjects had a mean duration of epilepsy of approximately 21.06 years. Between 85.3% and 89.1% of patients were taking two to three concomitant AEDs with or without concurrent vagal nerve stimulation.

Two studies (studies 304 and 305) compared doses of perampanel 8 and 12 mg/day with placebo and the third study (study 306) compared doses of perampanel 2, 4 and 8 mg/day with placebo. In all three trials, following a 6-week Baseline Phase to establish baseline seizure frequency prior to randomisation, subjects were randomised and titrated to the randomised dose. During the Titration Phase in all three trials, treatment was initiated at 2 mg/day and increased in weekly increments of 2 mg/day to the target dose. Subjects experiencing intolerable adverse events could remain on the same dose or have their dose decreased to the previously tolerated dose. In all three trials, the Titration Phase was followed by a Maintenance Phase that lasted 13 weeks, during which patients were to remain on a stable dose of perampanel.

The pooled 50% responder rates were placebo 19%, 4 mg 29%, 8 mg 35% and 12 mg 35%. A statistically significant effect on the reduction in 28-day seizure frequency (Baseline to Treatment Phase) as compared to the placebo group was observed with perampanel treatment at doses of 4 mg/day (Study 306), 8 mg/day (Studies 304, 305 and 306), and 12 mg/day (Studies 304 and 305). The 50% responder rates in the 4 mg, 8 mg and 12 mg groups were respectively 23.0%, 31.5%, and 30.0% in combination with enzyme-inducing anti-epileptic medicinal products and were 33.3%, 46.5% and 50.0% when perampanel was given in combination with non-enzyme-inducing anti-epileptic medicinal products. These studies show that once-daily administration of perampanel at doses of 4 mg to 12 mg was significantly more efficacious than placebo as adjunctive treatment in this population.

Data from placebo-controlled studies demonstrate that improvement in seizure control is observed with a once-daily perampanel dose of 4 mg and this benefit is enhanced as the dose is increased to 8 mg/day. No efficacy benefit was observed at the dose of 12 mg as compared to the dose of 8 mg in the overall population. Benefit at the dose of 12 mg was observed in some patients who tolerate the dose of 8 mg and when the clinical response to that dose was insufficient. A clinically meaningful reduction in seizure frequency relative to placebo was achieved as early as the second week of dosing when patients reached a daily dose of 4 mg.

1.7 to 5.8% of the patients on perampanel in the clinical studies became seizure free during the 3 month maintenance period compared with 0%-1.0% on placebo.

Open label extension study

Ninety-seven percent of the patients who completed the randomised trials in patients with partial-onset seizures were enrolled in the open label extension study (n = 1186). Patients from the randomised trial were converted to perampanel over 16 weeks followed by a long term maintenance period (≥ 1 year). The mean average daily dose was 10.05 mg.

Primary Generalised Tonic-Clonic Seizures

Perampanel as adjunctive therapy in patients 12 years of age and older with idiopathic generalised epilepsy experiencing primary generalised tonic-clonic seizures was established in a multicenter, randomised, double-blind, placebo-controlled study (Study 332). Eligible patients on a stable dose of 1 to 3 AEDs experiencing at least 3 primary generalised tonic-clonic seizures during the 8-week baseline period were randomised to either perampanel or placebo. The population included 164 patients (perampanel N = 82, placebo N = 82). Patients were titrated over four weeks to a target dose of 8 mg per day or the highest tolerated dose and treated for an additional 13 weeks on the last dose level achieved at the end of the titration period. The total treatment period was 17 weeks. Study drug was given once per day.
The 50% primary generalised tonic-clonic seizures responder rate during the Maintenance Period was significantly higher in the perampanel group (58.0%) than in the placebo group (35.8%), \( P = 0.0059 \). The 50% responder rate was 22.2% in combination with enzyme-inducing anti-epileptic medicinal products and was 69.4% when perampanel was given in combination with non-enzyme-inducing anti-epileptic medicinal products. The number of perampanel subjects taking enzyme-inducing anti-epileptic medicinal products was small \((n = 9)\). The median percent change in primary generalised tonic-clonic seizure frequency per 28 days during the Titration and Maintenance Periods (combined) relative to Prerandomisation was greater with perampanel \((-76.5\%)\) than with placebo \((-38.4\%)\), \( P < 0.0001 \). During the 3 months maintenance period, 30.9\% (25/81) of the patients on perampanel in the clinical studies became free of PGTC seizures compared with 12.3\% (10/81) on placebo.

Other subtypes of idiopathic generalised seizure

The efficacy and safety of perampanel in patients with myoclonic seizures have not been established. The available data are insufficient to reach any conclusions. The efficacy of perampanel in the treatment of absence seizures has not been demonstrated. In Study 332, in patients with PGTC seizures who also had concomitant myoclonic seizures, freedom from seizures was achieved in 16.7\% (4/24) on perampanel compared to 13.0\% (3/23) in those on placebo. In patients with concomitant absence seizures, freedom from seizures was achieved in 22.2\% (6/27) on perampanel compared to 12.1\% (4/33) on placebo. Freedom from all seizures was achieved in 23.5\% (19/81) of patients on perampanel compared to 4.9\% (4/81) of patients on placebo.

Open label extension phase

Of the 140 subjects who completed the Study 332, 114 subjects (81.4\%) had entered the Extension phase. Patients from the randomised trial were converted to perampanel over 6 weeks followed by a long term maintenance period \((\geq 1\text{ year})\). In the Extension Phase, 73.7\% of subjects have a modal daily perampanel dose of greater than 4 to 8 mg/day and 16.7\% had a modal daily dose of greater than 8 to 12 mg/day. A decrease in PGTC seizure frequency of at least 50\% was seen in 65.9\% of subjects after 1 year of treatment during the Extension Phase (relative to their pre-perampanel baseline seizure frequency). These data were consistent with those for percent change in seizure frequency and showed that the PGTC 50% responder rate was generally stable across time from about week 26 through the end of year 2. Similar results were seen when all seizures and absence vs. myoclonic seizures were evaluated over time.

Conversion to monotherapy

In a retrospective study of clinical practice, 51 patients with epilepsy who received perampanel as adjunctive treatment converted to perampanel monotherapy. The majority of these patients had a history of partial onset seizures. Of these, 14 patients (27\%) reverted to adjunctive therapy in the following months. Thirty four (34) patients were followed up for at least 6 months and, of these, 24 patients (71\%) remained on perampanel monotherapy for at least 6 months. Ten (10) patients were followed up for at least 18 months and, of these, 3 patients (30\%) remained on perampanel monotherapy for at least 18 months.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Fycompa in one or more subsets of the paediatric population in treatment-resistant epilepsies (localisation-related and age-related epilepsy syndromes) (see section 4.2 for information on adolescent use).

The three pivotal double-blind placebo-controlled phase 3 studies included 143 adolescents between the ages of 12 and 18. The results in these adolescents were similar to those seen in the adult population.

Study 332 included 22 adolescents between the ages of 12 and 18. The results in these adolescents were similar to those seen in the adult population.
A 19-week, randomised, double-blind, placebo-controlled study with an open-label extension phase (Study 235) was performed to assess the short-term effects on cognition of Fycompa (target dose range of 8 to 12 mg once daily) as adjunctive therapy in 133 (Fycompa n = 85, placebo n = 48) adolescent patients, ages 12 to less than 18 years old, with inadequately controlled partial-onset seizures. Cognitive function was assessed by the Cognitive Drug Research (CDR) System Global Cognition t-Score, which is a composite score derived from 5 domains testing Power of Attention, Continuity of Attention, Quality of Episodic Secondary Memory, Quality of Working Memory, and Speed of Memory. The mean change (SD) from baseline to end of double-blind treatment (19 weeks) in CDR System Global Cognition t-Score was 1.1 (7.14) in the placebo group and (minus) –1.0 (8.86) in the perampanel group, with the difference between the treatment groups in LS means (95% CI) = (minus) -2.2 (-5.2, 0.8). There was no statistically significant difference between the treatment groups (p = 0.145). CDR System Global Cognition t-Scores for placebo and perampanel were 41.2 (10.7) and 40.8 (13.0), respectively at the baseline. For patients with perampanel in the open label extension (n = 112), the mean change (SD) from baseline to end of open-label treatment (52 weeks) in CDR System Global Cognition t-Score was (minus) -1.0 (9.91). This was not statistically significant (p = 0.96). After up to 52 weeks of treatment with perampanel (n = 114), no effect on bone growth was observed. No effects on weight, height and sexual development were seen following up to 104 weeks of treatment (n = 114).

5.2 Pharmacokinetic properties

The pharmacokinetics of perampanel have been studied in healthy adult subjects (age range 18 to 79), adults and adolescents with partial-onset seizures and primary generalised tonic-clonic seizures, adults with Parkinson’s disease, adults with diabetic neuropathy, adults with multiple sclerosis, and subjects with hepatic impairment.

Absorption

Perampanel is readily absorbed after oral administration with no evidence of marked first-pass metabolism. Co-administration of perampanel tablets with a high fat meal had no impact on the peak plasma exposure (C\text{max}) or total exposure (AUC\text{0-inf}) of perampanel. The t\text{max} was delayed by approximately 1 hour compared to that under fasted conditions.

Distribution

Data from in vitro studies indicate that perampanel is approximately 95% bound to plasma proteins.

In vitro studies show that perampanel is not a substrate or significant inhibitor of organic anion transporting polypeptides (OATP) 1B1 and 1B3, organic anion transporters (OAT) 1, 2, 3, and 4, organic cation transporters (OCT) 1, 2, and 3, and the efflux transporters P-glycoprotein and Breast Cancer Resistance Protein (BCRP).

Biotransformation

Perampanel is extensively metabolised via primary oxidation and sequential glucuronidation. The metabolism of perampanel is mediated primarily by CYP3A based on clinical study results in healthy subjects administered radiolabeled perampanel and supported by in vitro studies using recombinant human CYPs and human liver microsomes.

Following administration of radiolabeled perampanel, only trace amounts of perampanel metabolites were observed in plasma.

Elimination

Following administration of a radiolabeled perampanel dose to either 8 healthy adults or elderly subjects, approximately 30% of recovered radioactivity was found in the urine and 70% in the faeces.
In urine and faeces, recovered radioactivity was primarily composed of a mixture of oxidative and conjugated metabolites. In a population pharmacokinetic analysis of pooled data from 19 Phase 1 studies, the average $t_{1/2}$ of perampanel was 105 hours. When dosed in combination with the strong CYP3A inducer carbamazepine, the average $t_{1/2}$ was 25 hours.

**Linearity/non-linearity**

In healthy subjects, plasma concentrations of perampanel increased in direct proportion to administered doses over the range of 2 to 12 mg. In a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials, a linear relationship was found between dose and perampanel plasma concentrations.

**Special populations**

**Hepatic impairment**

The pharmacokinetics of perampanel following a single 1 mg dose were evaluated in 12 subjects with mild and moderate hepatic impairment (Child-Pugh A and B, respectively) compared with 12 healthy, demographically matched subjects. The mean apparent clearance of unbound perampanel in mildly impaired subjects was 188 ml/min vs. 338 ml/min in matched controls, and in moderately impaired subjects was 120 ml/min vs. 392 ml/min in matched controls. The $t_{1/2}$ was longer in mildly impaired (306 h vs. 125 h) and moderately impaired (295 h vs. 139 h) subjects compared to matched healthy subjects.

**Renal impairment**

The pharmacokinetics of perampanel have not been formally evaluated in patients with renal impairment. Perampanel is eliminated almost exclusively by metabolism followed by rapid excretion of metabolites; only trace amounts of perampanel metabolites are observed in plasma. In a population pharmacokinetic analysis of patients with partial-onset seizures having creatinine clearances ranging from 39 to 160 mL/min and receiving perampanel up to 12 mg/day in placebo-controlled clinical trials, perampanel clearance was not influenced by creatinine clearance. In a population pharmacokinetic analysis of patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in a placebo-controlled clinical study, perampanel clearance was not influenced by baseline creatinine clearance.

**Gender**

In a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials, perampanel clearance in females (0.54 l/h) was 18% lower than in males (0.66 l/h).

**Elderly (65 years of age and above)**

In a population pharmacokinetic analysis of patients with partial-onset seizures (age range 12 to 74 years) and primary generalised tonic-clonic seizures (age range 12 to 58 years), and receiving perampanel up to 8 or 12 mg/day in placebo-controlled clinical trials, no significant effect of age on perampanel clearance was found. A dose adjustment in the elderly is not considered to be necessary (see section 4.2).

**Paediatric population**

In a population pharmacokinetic analysis of the adolescent patients pooled from the Phase 2 and 3 clinical studies, there were no notable differences between this population and the overall population.

**Drug interaction studies**

**In vitro assessment of drug interactions**
Drug metabolising enzyme inhibition

In human liver microsomes, perampanel (30 µmol/l) had a weak inhibitory effect on CYP2C8 and UGT1A9 among major hepatic CYPs and UGTs.

Drug metabolising enzyme induction

Compared with positive controls (including phenobarbital, rifampicin), perampanel was found to weakly induce CYP2B6 (30 µmol/l) and CYP3A4/5 (≥ 3 µmol/l) among major hepatic CYPs and UGTs in cultured human hepatocytes.

5.3 Preclinical safety data

Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:

In the fertility study in rats, prolonged and irregular oestrous cycles were observed at the maximum tolerated dose (30 mg/kg) in females; however, these changes did not affect fertility and early embryonic development. There were no effects on male fertility.

The excretion into breast milk was measured in rats at 10 days post-partum. Levels peaked at one hour and were 3.65 times the levels in plasma.

In a pre- and postnatal development toxicity study in rats, abnormal delivery and nursing conditions were observed at maternally toxic doses, and the number of stillbirths was increased in offspring. Behavioural and reproductive development of the offspring was not affected, but some parameters of physical development showed some delay, which is probably secondary to the pharmacology-based CNS effects of perampanel. The placental transfer was relatively low; 0.09% or less of administered dose was detected in the foetus.

Nonclinical data reveal that perampanel was not genotoxic and had no carcinogenic potential. The administration of maximum tolerated doses to rats and monkeys resulted in pharmacologically-based CNS clinical signs and decreased terminal body weight. There were no changes directly attributable to perampanel in clinical pathology or histopathology.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Fycompa 2 mg, 4 mg film-coated tablets

Core
Lactose monohydrate
Low-substituted hydroxypropyl cellulose
Povidone K-29/32
Magnesium stearate (E470b)

Fycompa 6 mg, 8 mg, 10 mg, 12 mg film-coated tablets

Core
Lactose monohydrate
Low-substituted hydroxypropyl cellulose
Povidone K-29/32
Microcrystalline cellulose
Magnesium stearate (E470b)
Fycompa 2 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
Ferric oxide, yellow (E172)
Ferric oxide, red (E172)

Fycompa 4 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
Ferric oxide, red (E172)

Fycompa 6 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
Ferric oxide, red (E172)

Fycompa 8 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
Ferric oxide, red (E172)
Ferric oxide, black (E172)

Fycompa 10 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
Ferric oxide, yellow (E172)
FD&C Blue #2 Indigo carmine aluminium lake (E132)

Fycompa 12 mg film-coated tablets

Film coating
Hypromellose 2910
Talc
Macrogol 8000
Titanium dioxide (E171)
FD&C Blue #2 Indigo carmine aluminium lake (E132)
6.2 **Incompatibilities**

Not applicable.

6.3 **Shelf life**

5 years

6.4 **Special precautions for storage**

This medicinal product does not require any special storage conditions.

6.5 **Nature and contents of container**

PVC/aluminium blisters

Fycompa 2 mg film-coated tablets
Pack of 7 only for first week of dosing, 28 and 98

Fycompa 4 mg film-coated tablets
4 mg – packs of 7, 28, 84 and 98

Fycompa 6 mg film-coated tablets
6 mg – packs of 7, 28, 84 and 98

Fycompa 8 mg film-coated tablets
8 mg – packs of 7, 28, 84 and 98

Fycompa 10 mg film-coated tablets
10 mg – packs of 7, 28, 84 and 98

Fycompa 12 mg film-coated tablets
12 mg – packs of 7, 28, 84 and 98

Not all pack sizes may be marketed.

6.6 **Special precautions for disposal**

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom
tel: +44 (0)208 600 1400
fax: +44 (0)208 600 1401
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/776/001-023

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 23/07/2012
Date of latest renewal: 6 April 2017

10. DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
1. NAME OF THE MEDICINAL PRODUCT

Fycompa 0.5 mg/ml oral suspension

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of oral suspension contains 0.5 mg perampanel

Each bottle of 340 ml contains 170 mg perampanel

Excipient with known effect:
Each ml of oral suspension contains 175 mg sorbitol (E420).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral suspension
White to off-white suspension

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.

Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy (see section 5.1).

4.2 Posology and method of administration

Posology

Fycompa must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability.
Perampanel suspension should be taken orally once daily at bedtime.
It may be taken with or without food, but preferably always under the same conditions. Switching between the tablet and suspension formulation should be done with caution (see section 5.2).

Partial-Onset Seizures
Perampanel at doses of 4 mg/day to 12 mg/day has been shown to be effective therapy in partial-onset seizures.

Treatment with Fycompa should be initiated with a dose of 2 mg/day (4 ml/day). The dose may be increased based on clinical response and tolerability by increments of 2 mg (4 ml) (either weekly or every 2 weeks as per half-life considerations described below) to a maintenance dose of 4 mg/day (8 ml/day) to 8 mg/day (16 ml/day). Depending upon individual clinical response and tolerability at a dose of 8 mg/day (16 ml/day), the dose may be increased by increments of 2 mg/day (4 ml/day) to 12 mg/day (24 ml/day). Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 1-week intervals.
Primary Generalised Tonic-Clonic Seizures
Perampanel at a dose up to 8 mg/day has been shown to be effective in primary generalised tonic-clonic seizures.

Treatment with Fycompa should be initiated at a dose of 2 mg/day (4 ml/day). The dose may be increased based on clinical response and tolerability by increments of 2 mg (4 ml/day) (either weekly or every 2 weeks, as per half-life considerations described below) to a maintenance dose of up to 8 mg/day (16 ml/day). Depending upon individual clinical response and tolerability at a dose of 8 mg/day (16 ml/day), the dose may be increased up to 12 mg/day (24 ml/day), which may be effective in some patients (see section 4.4). Patients who are taking concomitant medicinal products that do not shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 2-week intervals. Patients who are taking concomitant medicinal products that shorten the half-life of perampanel (see section 4.5) should be titrated no more frequently than at 1-week intervals.

Withdrawal
It is recommended that discontinuation be undertaken gradually to minimise the potential for rebound seizures. However, due to its long half-life and subsequent slow decline in plasma concentrations, perampanel can be discontinued abruptly if absolutely needed.

Missed doses
Single missed dose: As perampanel has a long half-life, the patient should wait and take their next dose as scheduled.

If more than 1 dose has been missed, for a continuous period of less than 5 half-lives (3 weeks for patients not taking perampanel metabolism-inducing anti-epileptic drugs (AED), 1 week for patients taking perampanel metabolism-inducing AEDs (see section 4.5)), consideration should be given to re-start treatment from the last dose level.

If a patient has discontinued perampanel for a continuous period of more than 5 half-lives, it is recommended that initial dosing recommendations given above should be followed.

Elderly (65 years of age and above)
Clinical studies of Fycompa in epilepsy did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Analysis of safety information in 905 perampanel-treated elderly subjects (in double-blind studies conducted in non-epilepsy indications) revealed no age-related differences in the safety profile. In combination with the lack of age-related difference in perampanel exposure, the results indicate that dose-adjustment in the elderly is not required. Perampanel should be used with caution in elderly taking into account the drug interaction potential in polymedicated patients (see section 4.4).

Renal impairment
Dose adjustment is not required in patients with mild renal impairment. Use in patients with moderate or severe renal impairment or patients undergoing haemodialysis is not recommended.

Hepatic impairment
Dose increases in patients with mild and moderate hepatic impairment should be based on clinical response and tolerability. For patients with mild or moderate hepatic impairment, dosing can be initiated at 2 mg (4 ml). Patients should be up-titrated using 2 mg (4 ml) doses no faster than every 2 weeks based on tolerability and effectiveness. Perampanel dosing for patients with mild and moderate impairment should not exceed 8 mg. Use in patients with severe hepatic impairment is not recommended.

Paediatric population
The safety and efficacy of perampanel in children below 12 years of age have not been established yet. No data are available.
Method of administration

Fycompa is for oral use.

Preparation: The press-in-bottle adapter (PIBA) which is supplied in the product carton should be inserted firmly into the neck of the bottle before use and remain in place for the duration of the usage of the bottle. The oral syringe should be inserted into the PIBA and the dose withdrawn from the inverted bottle. The cap should be replaced after each use. The cap fits properly when the PIBA is in place.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Suicidal ideation

Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled trials of anti-epileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for perampanel. Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.

Nervous system disorders

Perampanel may cause dizziness and somnolence and therefore may influence the ability to drive or use machines (see section 4.7).

Oral contraceptives

At doses of 12 mg/day Fycompa may decrease the effectiveness of progestative-containing hormonal contraceptives; in this circumstance additional non-hormonal forms of contraception are recommended when using Fycompa (see section 4.5).

Falls

There appears to be an increased risk of falls, particularly in the elderly; the underlying reason is unclear.

Aggression

Aggressive and hostile behaviour has been reported in patients receiving perampanel therapy. In perampanel-treated patients in clinical trials, aggression, anger and irritability were reported more frequently at higher doses. Most of the reported events were either mild or moderate and patients recovered either spontaneously or with dose adjustment. However, thoughts of harming others, physical assault or threatening behaviour were observed in some patients (<1% in perampanel clinical studies). Patients and caregivers should be counselled to alert a healthcare professional immediately if significant changes in mood or patterns of behaviour are noted. The dosage of perampanel should be reduced if such symptoms occur and should be discontinued immediately if symptoms are severe.
Abuse potential

Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of perampanel abuse.

Concomitant CYP 3A inducing anti-epileptic medicinal products

Response rates after addition of perampanel at fixed doses were less when patients received concomitant CYP3A enzyme-inducing anti-epileptic medicinal products (carbamazepine, phenytoin, oxcarbazepine) as compared to response rates in patients who received concomitant non-enzyme-inducing anti-epileptic medicinal products. Patients’ response should be monitored when they are switching from concomitant non-inducer anti-epileptic medicinal products to enzyme inducing medicinal products and vice versa. Depending upon individual clinical response and tolerability, the dose may be increased or decreased 2 mg at a time (see section 4.2).

Other concomitant (non- anti-epileptic) cytochrome P450 inducing or inhibiting medicinal products

Patients should be closely monitored for tolerability and clinical response when adding or removing cytochrome P450 inducers or inhibitors, since perampanel plasma levels can be decreased or increased; the dose of perampanel may need to be adjusted accordingly.

Sorbitol

Fycompa contains sorbitol (E420); therefore patients with rare hereditary problems of fructose intolerance should not take this medicinal product.

Caution should be exercised when combining Fycompa oral suspension with other antiepileptic medications containing sorbitol, since a combined intake of over 1 gram of sorbitol may affect absorption of some drugs.

4.5 Interaction with other medicinal products and other forms of interaction

Fycompa is not considered a strong inducer or inhibitor of cytochrome P450 or UGT enzymes (see section 5.2).

Oral contraceptives

In healthy women receiving 12 mg (but not 4 or 8 mg/day) for 21 days concomitantly with a combined oral contraceptive, Fycompa was shown to decrease the levonorgestrel exposure (mean C_{max} and AUC values were each decreased by 40%). Ethinylestradiol AUC was not affected by Fycompa 12 mg whereas C_{max} was decreased by 18%. Therefore, the possibility of decreased efficacy of progestative-containing oral contraceptives should be considered for women needing Fycompa 12 mg/day and an additional reliable method (intra-uterine device (IUD), condom) is to be used (see section 4.4).

Interactions between Fycompa and other anti-epileptic medicinal products

Potential interactions between Fycompa (up to 12 mg once daily) and other anti-epileptic drugs (AEDs) were assessed in clinical studies and evaluated in the population PK analysis of four pooled Phase 3 studies including patients with partial-onset seizures and primary generalised tonic-clonic seizures. The effect of these interactions on average steady state concentration is summarised in the following table.
Some anti-epileptic drugs known as CYP450 3A enzyme inducers (carbamazepine, phenytoin, oxcarbazepine) have been shown to increase perampanel clearance and consequently to decrease plasma concentrations of perampanel. Conversely, withdrawal of a concomitant CYP450 3A enzyme inducer can be expected to increase plasma concentrations of perampanel and dose reduction may be required.

Carbamazepine, a known potent enzyme inducer, reduced perampanel levels by two-thirds in a study performed on healthy subjects.

A similar result was seen in a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials. The total clearance of Fycompa was increased when administered with carbamazepine (2.75-fold), phenytoin (1.7-fold) and oxcarbazepine (1.9-fold), which are known inducers of enzymes of metabolism (see section 5.2). This effect should be taken into account and managed when adding or withdrawing these anti-epileptic drugs from a patient’s treatment regimen.

In a population pharmacokinetic analysis of patients with partial-onset seizures receiving Fycompa up to 12 mg/day in placebo-controlled clinical trials, Fycompa did not affect to a clinically relevant manner the clearance of clonazepam, levetiracetam, phenobarbital, phenytoin, topiramate, zonisamide, carbamazepine, clobazam, lamotrigine and valproic acid, at the highest perampanel dose evaluated (12 mg/day).

In the epilepsy population pharmacokinetic analysis, perampanel was found to decrease the clearance of oxcarbazepine by 26%. Oxcarbazepine is rapidly metabolised by cytosolic reductase enzyme to the active metabolite, monohydroxycarbazepine. The effect of perampanel on monohydroxycarbazepine concentrations is not known.

Perampanel is dosed to clinical effect regardless of other AEDs.

**Effect of perampanel on CYP3A substrates**

In healthy subjects, Fycompa (6 mg once daily for 20 days) decreased midazolam AUC by 13%. A larger decrease in exposure of midazolam (or other sensitive CYP3A substrates) at higher Fycompa doses cannot be excluded.

**Effect of cytochrome P450 inducers on perampanel pharmacokinetics**

Strong inducers of cytochrome P450, such as rifampicin and hypericum, are expected to decrease perampanel concentrations and the potential for higher plasma concentrations of reactive metabolites.

---

<table>
<thead>
<tr>
<th>AED coadministered</th>
<th>Influence of AED on Fycompa concentration</th>
<th>Influence of Fycompa on AED concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>2.75 fold decrease</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Clobazam</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>1.9 fold decrease</td>
<td>35% increase 1)</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>No influence</td>
<td>No influence</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>1.7 fold decrease</td>
<td>No influence</td>
</tr>
<tr>
<td>Topiramate</td>
<td>19% decrease</td>
<td>No influence</td>
</tr>
<tr>
<td>Valproic Acid</td>
<td>No influence</td>
<td>&lt;10% decrease</td>
</tr>
<tr>
<td>Zonisamide</td>
<td>No influence</td>
<td>No influence</td>
</tr>
</tbody>
</table>

2) Active metabolite monohydroxycarbazepine was not assessed.

---
Felbamate has been shown to decrease the concentrations of some medicinal products and may also reduce perampanel concentrations.

**Effect of cytochrome P450 inhibitors on perampanel pharmacokinetics**

In healthy subjects, the CYP3A4 inhibitor ketoconazole (400 mg once daily for 10 days) increased perampanel AUC by 20% and prolonged perampanel half--life by 15% (67.8 h vs 58.4 h). Larger effects cannot be excluded when perampanel is combined with a CYP3A inhibitor with longer half-life than ketoconazole or when the inhibitor is given for a longer treatment duration.

**Levodopa**

In healthy subjects, Fycompa (4 mg once daily for 19 days) had no effect on C_{max} or AUC of levodopa.

**Alcohol**

The effects of perampanel on tasks involving alertness and vigilance such as driving ability were additive or supra-additive to the effects of alcohol itself, as found in a pharmacodynamic interaction study in healthy subjects. Multiple dosing of perampanel 12 mg/day increased levels of anger, confusion, and depression as assessed using the Profile of Mood State 5-point rating scale (see section 5.1). These effects may also be seen when Fycompa is used in combination with other central nervous system (CNS) depressants.

**Paediatric population**

Interaction studies have only been performed in adults.

In a population pharmacokinetic analysis of the adolescent patients in the Phase 3 clinical studies, there were no notable differences between this population and the overall population.

**4.6 Fertility, pregnancy and lactation**

**Women of childbearing potential and contraception in males and females**

Fycompa is not recommended in women of childbearing potential not using contraception unless clearly necessary.

**Pregnancy**

There are limited amounts of data (less than 300 pregnancy outcomes) from the use of perampanel in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats at maternally toxic doses (see section 5.3). Fycompa is not recommended during pregnancy.

**Breast-feeding**

Studies in lactating rats have shown excretion of perampanel and/or its metabolites in milk (for details see section 5.3). It is not known whether perampanel is excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fycompa therapy taking into account the benefit of breast--feeding for the child and the benefit of therapy for the woman.

**Fertility**

In the fertility study in rats, prolonged and irregular oestrous cycles were observed at high-dose (30 mg/kg) in females; however, these changes did not affect the fertility and early embryonic development. There were no effects on male fertility (see section 5.3). The effect of perampanel on human fertility has not been established.
4.7 Effects on ability to drive and use machines

Fycompa has moderate influence on the ability to drive and use machines. Perampanel may cause dizziness and somnolence and, therefore, may influence the ability to drive or use machines. Patients are advised not to drive a vehicle, operate complex machinery or engage in other potentially hazardous activities until it is known whether perampanel affects their ability to perform these tasks (see sections 4.4 and 4.5).

4.8 Undesirable effects

Summary of the safety profile

In all controlled and uncontrolled trials in patients with partial-onset seizures, 1,639 subjects have received perampanel of whom 1,147 have been treated for 6 months and 703 for longer than 12 months.

In the controlled and uncontrolled trial in patients with primary generalised tonic-clonic seizures, 114 subjects have received perampanel of whom 68 have been treated for 6 months and 36 for longer than 12 months.

Adverse reactions leading to discontinuation:
In the controlled Phase 3 partial-onset seizures clinical trials, the rate of discontinuation as a result of an adverse reaction was 1.7%, 4.2% and 13.7% in patients randomised to receive perampanel at the recommended doses of 4 mg, 8 mg and 12 mg/day, respectively, and 1.4% in patients randomised to receive placebo. The adverse reactions most commonly (≥ 1% in the total perampanel group and greater than placebo) leading to discontinuation were dizziness and somnolence.

In the controlled Phase 3 primary generalised tonic-clonic seizures clinical trial, the rate of discontinuation as a result of an adverse reaction was 4.9% in patients randomised to receive perampanel 8 mg, and 1.2% in patients randomised to receive placebo. The adverse reaction most commonly leading to discontinuation (≥ 2% in the perampanel group and greater than placebo) was dizziness.

Tabulated list of adverse reactions

In the table below, adverse reactions, which were identified based on review of the full Fycompa clinical studies safety database, are listed by System Organ Class and frequency. The following convention has been used for the classification of adverse reactions: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100).

Within each frequency category, adverse reactions are presented in order of decreasing seriousness.
<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Very common</th>
<th>Common</th>
<th>Uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
<td>Aggression</td>
<td>Suicidal ideation</td>
</tr>
<tr>
<td></td>
<td>Increased appetite</td>
<td>Anger</td>
<td>Suicide attempt</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td></td>
<td>Anxiety</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Confusional state</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dizziness</td>
<td>Ataxia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Dysarthria</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Balance disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irritability</td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td>Gait disturbance</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fatigue</td>
<td></td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vertigo</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td>Nausea</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
<td>Back pain</td>
<td></td>
</tr>
<tr>
<td>General disorders</td>
<td>Gait disturbance</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Weight increased</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>Fall</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Paediatric population**

Based on the clinical trial database of 196 adolescents exposed to perampanel from double-blind studies for partial-onset seizures and primary generalised tonic-clonic seizures, the overall safety profile in adolescents was similar to that of adults, except for aggression, which was observed more frequently in adolescents than in adults.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

There is limited clinical experience with perampanel overdose in humans. In a report of an intentional overdose that could have resulted in a dose up to 264 mg, the patient experienced events of altered mental status, agitation and aggressive behaviour and recovered without sequelae. There is no available specific antidote to the effects of perampanel. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient. In view of its long half-life, the effects caused by perampanel could be prolonged. Because of low renal clearance special interventions such as forced diuresis, dialysis or haemoperfusion are unlikely to be of value.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX22
Mechanism of action

Perampanel is a first-in-class selective, non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons. Glutamate is the primary excitatory neurotransmitter in the central nervous system and is implicated in a number of neurological disorders caused by neuronal overexcitation. Activation of AMPA receptors by glutamate is thought to be responsible for most fast excitatory synaptic transmission in the brain. In in vitro studies, perampanel did not compete with AMPA for binding to the AMPA receptor, but perampanel binding was displaced by noncompetitive AMPA receptor antagonists, indicating that perampanel is a noncompetitive AMPA receptor antagonist. In vitro, perampanel inhibited AMPA-induced (but not NMDA-induced) increase in intracellular calcium. In vivo, perampanel significantly prolonged seizure latency in an AMPA-induced seizure model.

The precise mechanism by which perampanel exerts its antiepileptic effects in humans remains to be fully elucidated.

Pharmacodynamic effects

A pharmacokinetic-pharmacodynamic (efficacy) analysis was performed based on the pooled data from the 3 efficacy trials for partial-onset seizures. In addition, a pharmacokinetic-pharmacodynamic (efficacy) analysis was performed in one efficacy trial for primary generalised tonic-clonic seizures. In both analyses, perampanel exposure is correlated with reduction in seizure frequency.

Psychomotor performance

Single and multiple doses of 8 mg and 12 mg impaired psychomotor performance in healthy volunteers in a dose-related manner. The effects of perampanel on complex tasks such as driving ability were additive or supra-additive to the impairment effects of alcohol. Psychomotor performance testing returned to baseline within 2 weeks of cessation of perampanel dosing.

Cognitive function

In a healthy volunteer study to assess the effects of perampanel on alertness, and memory using a standard battery of assessments, no effects of perampanel were found following single and multiple doses of perampanel up to 12 mg/day.

In a placebo controlled study conducted in adolescent patients, no significant changes in cognition relative to placebo as measured by Cognitive Drug Research (CDR) System Global Cognition Score were observed for perampanel. In the open label extension, no significant changes were observed in global CDR system score after 52 weeks of perampanel treatment (see section 5.1 Paediatric population).

Alertness and mood

Levels of alertness (arousal) decreased in a dose-related manner in healthy subjects dosed with perampanel from 4 to 12 mg/day. Mood deteriorated following dosing of 12 mg/day only; the changes in mood were small and reflected a general lowering of alertness. Multiple dosing of perampanel 12 mg/day also enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion and depression as assessed using the Profile of Mood State 5-point rating scale.

Cardiac electrophysiology

Perampanel did not prolong the QTc interval when administered in daily doses up to 12 mg/day, and did not have a dose-related or clinically important effect on QRS duration.

Clinical efficacy and safety

Partial-Onset Seizures

The efficacy of perampanel in partial-onset seizures was established in three adjunctive therapy 19 week, randomised, double-blind, placebo-controlled, multicentre trials in adult and adolescent
patients. Subjects had partial-onset seizures with or without secondary generalisation and were not adequately controlled with one to three concomitant AEDs. During a 6-week baseline period, subjects were required to have more than five seizures with no seizure-free period exceeding 25 days. In these three trials, subjects had a mean duration of epilepsy of approximately 21.06 years. Between 85.3% and 89.1% of patients were taking two to three concomitant AEDs with or without concurrent vagal nerve stimulation.

Two studies (studies 304 and 305) compared doses of perampanel 8 and 12 mg/day with placebo and the third study (study 306) compared doses of perampanel 2, 4 and 8 mg/day with placebo. In all three trials, following a 6-week Baseline Phase to establish baseline seizure frequency prior to randomisation, subjects were randomised and titrated to the randomised dose. During the Titration Phase in all three trials, treatment was initiated at 2 mg/day and increased in weekly increments of 2 mg/day to the target dose. Subjects experiencing intolerable adverse events could remain on the same dose or have their dose decreased to the previously tolerated dose. In all three trials, the Titration Phase was followed by a Maintenance Phase that lasted 13 weeks, during which patients were to remain on a stable dose of perampanel.

The pooled 50% responder rates were placebo 19%, 4 mg 29%, 8 mg 35% and 12 mg 35%. A statistically significant effect on the reduction in 28-day seizure frequency (Baseline to Treatment Phase) as compared to the placebo group was observed with perampanel treatment at doses of 4 mg/day (Study 306), 8 mg/day (Studies 304, 305 and 306), and 12 mg/day (Studies 304 and 305). The 50% responder rates in the 4 mg, 8 mg and 12 mg groups were respectively 23.0%, 31.5%, and 30.0% in combination with enzyme-inducing anti-epileptic medicinal products and were 33.3%, 46.5% and 50.0% when perampanel was given in combination with non-enzyme-inducing anti-epileptic medicinal products. These studies show that once-daily administration of perampanel at doses of 4 mg to 12 mg was significantly more efficacious than placebo as adjunctive treatment in this population.

Data from placebo-controlled studies demonstrate that improvement in seizure control is observed with a once-daily perampanel dose of 4 mg and this benefit is enhanced as the dose is increased to 8 mg/day. No efficacy benefit was observed at the dose of 12 mg as compared to the dose of 8 mg in the overall population. Benefit at the dose of 12 mg was observed in some patients who tolerate the dose of 8 mg and when the clinical response to that dose was insufficient. A clinically meaningful reduction in seizure frequency relative to placebo was achieved as early as the second week of dosing when patients reached a daily dose of 4 mg.

1.7 to 5.8% of the patients on perampanel in the clinical studies became seizure free during the 3 month maintenance period compared with 0%-1.0% on placebo.

Open label extension study
Ninety-seven percent of the patients who completed the randomised trials in patients with partial-onset seizures were enrolled in the open label extension study (n = 1186). Patients from the randomised trial were converted to perampanel over 16 weeks followed by a long term maintenance period (≥ 1 year). The mean average daily dose was 10.05 mg.

Primary Generalised Tonic-Clonic Seizures
Perampanel as adjunctive therapy in patients 12 years of age and older with idiopathic generalised epilepsy experiencing primarily generalised tonic-clonic seizures was established in a multicenter, randomised, double-blind, placebo-controlled study (Study 332). Eligible patients on a stable dose of 1 to 3 AEDs experiencing at least 3 primary generalised tonic-clonic seizures during the 8-week baseline period were randomised to either perampanel or placebo. The population included 164 patients (perampanel N = 82, placebo N = 82). Patients were titrated over four weeks to a target dose of 8 mg per day or the highest tolerated dose and treated for an additional 13 weeks on the last dose level achieved at the end of the titration period. The total treatment period was 17 weeks. Study drug was given once per day.
The 50% primary generalised tonic-clonic seizures responder rate during the Maintenance Period was significantly higher in the perampanel group (58.0%) than in the placebo group (35.8%), P = 0.0059. The 50% responder rate was 22.2% in combination with enzyme-inducing anti-epileptic medicinal products and was 69.4% when perampanel was given in combination with non-enzyme-inducing anti-epileptic medicinal products. The number of perampanel subjects taking enzyme-inducing anti-epileptic medicinal products was small (n = 9). The median percent change in primary generalised tonic-clonic seizure frequency per 28 days during the Titration and Maintenance Periods (combined) relative to Prerandomisation was greater with perampanel (-76.5%) than with placebo (-38.4%), P < 0.0001. During the 3 months maintenance period, 30.9% (25/81) of the patients on perampanel in the clinical studies became free of PGTC seizures compared with 12.3% (10/81) on placebo.

Other subtypes of idiopathic generalised seizure
The efficacy and safety of perampanel in patients with myoclonic seizures have not been established. The available data are insufficient to reach any conclusions. The efficacy of perampanel in the treatment of absence seizures has not been demonstrated. In Study 332, in patients with PGTC seizures who also had concomitant myoclonic seizures, freedom from seizures was achieved in 16.7% (4/24) on perampanel compared to 13.0% (3/23) in those on placebo. In patients with concomitant absence seizures, freedom from seizures was achieved in 22.2% (6/27) on perampanel compared to 12.1% (4/33) on placebo. Freedom from all seizures was achieved in 23.5% (19/81) of patients on perampanel compared to 4.9% (4/81) of patients on placebo.

Open label extension phase
Of the 140 subjects who completed the Study 332, 114 subjects (81.4%) had entered the Extension phase. Patients from the randomised trial were converted to perampanel over 6 weeks followed by a long term maintenance period (≥ 1 year). In the Extension Phase, 73.7% of subjects have a modal daily perampanel dose of greater than 4 to 8 mg/day and 16.7% had a modal daily dose of greater than 8 to 12 mg/day. A decrease in PGTC seizure frequency of at least 50% was seen in 65.9% of subjects after 1 year of treatment during the Extension Phase (relative to their pre-perampanel baseline seizure frequency). These data were consistent with those for percent change in seizure frequency and showed that the PGTC 50% responder rate was generally stable across time from about week 26 through the end of year 2. Similar results were seen when all seizures and absence vs. myoclonic seizures were evaluated over time.

Conversion to monotherapy
In a retrospective study of clinical practice, 51 patients with epilepsy who received perampanel as adjunctive treatment converted to perampanel monotherapy. The majority of these patients had a history of partial onset seizures. Of these, 14 patients (27%) reverted to adjunctive therapy in the following months. Thirty four (34) patients were followed up for at least 6 months and, of these, 24 patients (71%) remained on perampanel monotherapy for at least 6 months. Ten (10) patients were followed up for at least 18 months and, of these, 3 patients (30%) remained on perampanel monotherapy for at least 18 months.

Paediatric population
The European Medicines Agency has deferred the obligation to submit the results of studies with Fycompa in one or more subsets of the paediatric population in treatment-resistant epilepsies (localisation-related and age-related epilepsy syndromes) (see section 4.2 for information on adolescent use).

The three pivotal double-blind placebo-controlled phase 3 studies included 143 adolescents between the ages of 12 and 18. The results in these adolescents were similar to those seen in the adult population.

Study 332 included 22 adolescents between the ages of 12 and 18. The results in these adolescents were similar to those seen in the adult population.
A 19-week, randomised, double-blind, placebo-controlled study with an open-label extension phase (Study 235) was performed to assess the short-term effects on cognition of Fycompa (target dose range of 8 to 12 mg once daily) as adjunctive therapy in 133 (Fycompa n = 85, placebo n = 48) adolescent patients, ages 12 to less than 18 years old, with inadequately controlled partial-onset seizures. Cognitive function was assessed by the Cognitive Drug Research (CDR) System Global Cognition t-Score, which is a composite score derived from 5 domains testing Power of Attention, Continuity of Attention, Quality of Episodic Secondary Memory, Quality of Working Memory, and Speed of Memory. The mean change (SD) from baseline to end of double-blind treatment (19 weeks) in CDR System Global Cognition t-Score was 1.1 (7.14) in the placebo group and (minus) –1.0 (8.86) in the perampanel group, with the difference between the treatment groups in LS means (95% CI) = (minus) -2.2 (-5.2, 0.8). There was no statistically significant difference between the treatment groups (p = 0.145). CDR System Global Cognition t-Scores for placebo and perampanel were 41.2 (10.7) and 40.8 (13.0), respectively at the baseline. For patients with perampanel in the open label extension (n = 112), the mean change (SD) from baseline to end of open-label treatment (52 weeks) in CDR System Global Cognition t-Score was (minus) -1.0 (9.91). This was not statistically significant (p = 0.96). After up to 52 weeks of treatment with perampanel (n = 114), no effect on bone growth was observed. No effects on weight, height and sexual development were seen following up to 104 weeks of treatment (n = 114).

5.2 Pharmacokinetic properties

The pharmacokinetics of perampanel have been studied in healthy adult subjects (age range 18 to 79), adults and adolescents with partial-onset seizures and primary generalised tonic-clonic seizures, adults with Parkinson’s disease, adults with diabetic neuropathy, adults with multiple sclerosis, and subjects with hepatic impairment.

Absorption

Perampanel is readily absorbed after oral administration with no evidence of marked first-pass metabolism.

Perampanel oral suspension is bioequivalent on a mg per mg basis to perampanel tablets under fasted conditions. When a single 12-mg dose of both formulations was administered with a high fat meal, perampanel oral suspension achieves equivalent AUC\(_{0-\infty}\) and approximately 23 % lower C\(_{\text{max}}\) and 2 hours delay in time to peak exposure (t\(_{\text{max}}\)) compared to the tablet formulation. However, population pharmacokinetic analysis demonstrated that under simulated steady state exposure conditions, C\(_{\text{max}}\) and AUC, of perampanel oral suspension were bioequivalent to the tablet formulation under both fasted and fed conditions.

When coadministered with a high fat meal, C\(_{\text{max}}\) and AUC\(_{0-\infty}\) of a single 12-mg dose of perampanel oral suspension were approximately 22% and 13%, respectively, lower compared to fasted conditions.

Distribution

Data from in vitro studies indicate that perampanel is approximately 95% bound to plasma proteins.

In vitro studies show that perampanel is not a substrate or significant inhibitor of organic anion transporting polypeptides (OATP) 1B1 and 1B3, organic anion transporters (OAT) 1, 2, 3, and 4, organic cation transporters (OCT) 1, 2, and 3, and the efflux transporters P-glycoprotein and Breast Cancer Resistance Protein (BCRP).

Biotransformation

Perampanel is extensively metabolised via primary oxidation and sequential glucuronidation. The metabolism of perampanel is mediated primarily by CYP3A based on clinical study results in healthy...
subjects administered radiolabeled perampanel and supported by in vitro studies using recombinant human CYPs and human liver microsomes.

Following administration of radiolabeled perampanel, only trace amounts of perampanel metabolites were observed in plasma.

**Elimination**

Following administration of a radiolabeled perampanel dose to either 8 healthy adults or elderly subjects, approximately 30% of recovered radioactivity was found in the urine and 70% in the faeces. In urine and faeces, recovered radioactivity was primarily composed of a mixture of oxidative and conjugated metabolites. In a population pharmacokinetic analysis of pooled data from 19 Phase 1 studies, the average $t_{1/2}$ of perampanel was 105 hours. When dosed in combination with the strong CYP3A inducer carbamazepine, the average $t_{1/2}$ was 25 hours.

**Linearity/non-linearity**

In healthy subjects, plasma concentrations of perampanel increased in direct proportion to administered doses over the range of 2 to 12 mg. In a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials, a linear relationship was found between dose and perampanel plasma concentrations.

**Special populations**

*Hepatic impairment*

The pharmacokinetics of perampanel following a single 1 mg dose were evaluated in 12 subjects with mild and moderate hepatic impairment (Child-Pugh A and B, respectively) compared with 12 healthy, demographically matched subjects. The mean apparent clearance of unbound perampanel in mildly impaired subjects was 188 ml/min vs. 338 ml/min in matched controls, and in moderately impaired subjects was 120 ml/min vs. 392 ml/min in matched controls. The $t_{1/2}$ was longer in mildly impaired (306 h vs. 125 h) and moderately impaired (295 h vs. 139 h) subjects compared to matched healthy subjects.

*Renal impairment*

The pharmacokinetics of perampanel have not been formally evaluated in patients with renal impairment. Perampanel is eliminated almost exclusively by metabolism followed by rapid excretion of metabolites; only trace amounts of perampanel metabolites are observed in plasma. In a population pharmacokinetic analysis of patients with partial-onset seizures having creatinine clearances ranging from 39 to 160 mL/min and receiving perampanel up to 12 mg/day in placebo-controlled clinical trials, perampanel clearance was not influenced by creatinine clearance. In a population pharmacokinetic analysis of patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in a placebo-controlled clinical study, perampanel clearance was not influenced by baseline creatinine clearance.

*Gender*

In a population pharmacokinetic analysis of patients with partial-onset seizures receiving perampanel up to 12 mg/day and patients with primary generalised tonic-clonic seizures receiving perampanel up to 8 mg/day in placebo-controlled clinical trials, perampanel clearance in females (0.54 l/h) was 18% lower than in males (0.66 l/h).

*Elderly (65 years of age and above)*

In a population pharmacokinetic analysis of patients with partial-onset seizures (age range 12 to 74 years) and primary generalised tonic-clonic seizures (age range 12 to 58 years), and receiving perampanel up to 8 or 12 mg/day in placebo-controlled clinical trials, no significant effect of age on
perampanel clearance was found. A dose adjustment in the elderly is not considered to be necessary (see section 4.2).

**Paediatric population**
In a population pharmacokinetic analysis of the adolescent patients pooled from the Phase 2 and 3 clinical studies, there were no notable differences between this population and the overall population.

**Drug interaction studies**

**In vitro assessment of drug interactions**

*Drug metabolising enzyme inhibition*
In human liver microsomes, perampanel (30 µmol/l) had a weak inhibitory effect on CYP2C8 and UGT1A9 among major hepatic CYPs and UGTs.

*Drug metabolising enzyme induction*
Compared with positive controls (including phenobarbital, rifampicin), perampanel was found to weakly induce CYP2B6 (30 µmol/l) and CYP3A4/5 (≥ 3 µmol/l) among major hepatic CYPs and UGTs in cultured human hepatocytes.

5.3 Preclinical safety data

Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:

In the fertility study in rats, prolonged and irregular oestrous cycles were observed at the maximum tolerated dose (30 mg/kg) in females; however, these changes did not affect fertility and early embryonic development. There were no effects on male fertility.

The excretion into breast milk was measured in rats at 10 days post-partum. Levels peaked at one hour and were 3.65 times the levels in plasma.

In a pre- and postnatal development toxicity study in rats, abnormal delivery and nursing conditions were observed at maternally toxic doses, and the number of stillbirths was increased in offspring. Behavioural and reproductive development of the offspring was not affected, but some parameters of physical development showed some delay, which is probably secondary to the pharmacology-based CNS effects of perampanel. The placental transfer was relatively low; 0.09% or less of administered dose was detected in the foetus.

Nonclinical data reveal that perampanel was not genotoxic and had no carcinogenic potential. The administration of maximum tolerated doses to rats and monkeys resulted in pharmacologically-based CNS clinical signs and decreased terminal body weight. There were no changes directly attributable to perampanel in clinical pathology or histopathology.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sorbitol (E420) liquid (crystallising)
Microcrystalline cellulose (E460)
Carmellose sodium (E466)
Poloxamer 188
Simethicone emulsion 30%, containing purified water, silicone oil, polysorbate 65, methylcellulose, silica gel, macrogol stearate, sorbic acid, benzoic acid and sulfuric acid
Citric acid, anhydrous (E330)
Sodium benzoate (E211)
Purified water

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
2 years
After first opening: 90 days.

6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container
Polyethylene terephthalate (PET) bottle with a child-resistant (CR) polypropylene (PP) closure; each bottle contains 340 ml of suspension in an outer cardboard carton.

Each carton contains one bottle, two 20 mL graduated oral dosing syringes and an LDPE press-in bottle adapter (PIBA). The oral dosing syringes are graduated in 0.5 ml increments.

6.6 Special precautions for disposal
No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER
Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom
tel: +44 (0)208 600 1400
fax: +44 (0)208 600 1401
e-mail: EUmedinfo@eisai.net

8. MARKETING AUTHORISATION NUMBER(S)
EU/1/12/776/024

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 23/07/2012
Date of latest renewal: 6 April 2017
10. DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Eisai Manufacturing Ltd.
European Knowledge Centre
Mosquito Way
Hatfield, Herts AL10 9SN
United Kingdom

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Carton of 7, 28 and 98 tablets

1. NAME OF THE MEDICINAL PRODUCT

Fycompa 2 mg film-coated tablets
Perampanel

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 2 mg perampanel.

3. LIST OF EXCIPIENTS

Contains lactose: see leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

7 film-coated tablets
28 film-coated tablets
98 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/776/001
EU/1/12/776/017
EU/1/12/776/018

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fycompa 2 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blister Pack (PVC/Aluminium blister)</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Fycompa 2 mg tablets  
   Perampanel

2. **NAME OF THE MARKETING AUTHORISATION HOLDER**

   Eisai

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **OTHER**
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Cartons of 7, 28, 84 and 98 tablets

1. NAME OF THE MEDICINAL PRODUCT
Fycompa 4 mg film-coated tablets
Perampanel

2. STATEMENT OF ACTIVE SUBSTANCE(S)
Each tablet contains 4 mg perampanel.

3. LIST OF EXCIPIENTS
Contains lactose: see leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS
7 film-coated tablets
28 film-coated tablets
84 film-coated tablets
98 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION
Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN
Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE
EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eisai Europe Limited  
European Knowledge Centre  
Mosquito Way  
Hatfield  
Hertfordshire  
AL10 9SN  
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/776/002  
EU/1/12/776/003  
EU/1/12/776/004  
EU/1/12/776/019

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fycompa 4 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:  
SN:  
NN:
<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fycompa 4 mg tablets</td>
</tr>
<tr>
<td>Perampanel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Cartons of 7, 28, 84 and 98 tablets

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Fycompa 6 mg film-coated tablets
   Perampanel

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**
   
   Each tablet contains 6 mg perampanel.

3. **LIST OF EXCIPIENTS**
   
   Contains lactose: see leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**
   
   7 film-coated tablets
   28 film-coated tablets
   84 film-coated tablets
   98 film-coated tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**
   
   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**
   
   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/776/005
EU/1/12/776/006
EU/1/12/776/007
EU/1/12/776/020

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fycompa 6 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
<table>
<thead>
<tr>
<th>MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blister Pack (PVC/Aluminium blister)</td>
</tr>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
</tr>
<tr>
<td>Fycompa 6 mg tablets</td>
</tr>
<tr>
<td>Perampanel</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORITY HELDER</strong></td>
</tr>
<tr>
<td>Eisai</td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
</tr>
<tr>
<td>EXP</td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
</tr>
<tr>
<td>Lot</td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
</tr>
<tr>
<td>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</td>
</tr>
<tr>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Cartons of 7, 28, 84 and 98 tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fycompa 8 mg film-coated tablets</td>
</tr>
<tr>
<td>Perampanel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each tablet contains 8 mg perampanel.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contains lactose: see leaflet for further information.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 film-coated tablets</td>
</tr>
<tr>
<td>28 film-coated tablets</td>
</tr>
<tr>
<td>84 film-coated tablets</td>
</tr>
<tr>
<td>98 film-coated tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
</table>

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/12/776/008
EU/1/12/776/009
EU/1/12/776/010
EU/1/12/776/021

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fycompa 8 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**Blister Pack (PVC/Aluminium blister)**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fycompa 8 mg tablets</td>
<td>Perampanel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
<th></th>
</tr>
</thead>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Cartons of 7, 28, 84 and 98 tablets

1. NAME OF THE MEDICINAL PRODUCT

Fycompa 10 mg film-coated tablets
Perampanel

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 10 mg perampanel.

3. LIST OF EXCIPIENTS

Contains lactose: see leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

7 film-coated tablets
28 film-coated tablets
84 film-coated tablets
98 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/12/776/011
EU/1/12/776/012
EU/1/12/776/013
EU/1/12/776/022

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fycompa 10 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
## MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

### Blister Pack (PVC/Aluminium blister)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
</tbody>
</table>
|   | Fycompa 10 mg tablets  
|   | Perampanel |
| **2. NAME OF THE MARKETING AUTHORISATION HOLDER** |   |
|   | Eisai |
| **3. EXPIRY DATE** |   |
|   | EXP |
| **4. BATCH NUMBER** |   |
|   | Lot |
| **5. OTHER** |   |
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Cartons of 7, 28, 84 and 98 tablets

1. NAME OF THE MEDICINAL PRODUCT

Fycompa 12 mg film-coated tablets
Perampanel

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each tablet contains 12 mg perampanel.

3. LIST OF EXCIPIENTS

Contains lactose: see leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

7 film-coated tablets
28 film-coated tablets
84 film-coated tablets
98 film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

   Eisai Europe Limited  
   European Knowledge Centre  
   Mosquito Way  
   Hatfield  
   Hertfordshire  
   AL10 9SN  
   United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

   EU/1/12/776/014  
   EU/1/12/776/015  
   EU/1/12/776/016  
   EU/1/12/776/023

13. **BATCH NUMBER**

   Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

   Fycompa 12 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

   2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

   PC:  
   SN:  
   NN:
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

*Blister Pack (PVC/Aluminium blister)*

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fycompa 12 mg tablets</td>
</tr>
<tr>
<td>Perampanel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

1. NAME OF THE MEDICINAL PRODUCT

Fycompa 0.5 mg/ml oral suspension
perampanel

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each ml contains 0.5 mg perampanel.
1 bottle (340 ml) contains 170 mg perampanel.

3. LIST OF EXCIPIENTS

Contains sorbitol: see leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Oral suspension 340 ml.
1 bottle
2 oral syringes
1 press-in-bottle adapter (PIBA)

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Shake for at least 5 seconds before use.
Oral use
Open date:

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY
8. **EXPIRY DATE**

EXP
After first opening: use within 90 days.

9. **SPECIAL STORAGE CONDITIONS**

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Hatfield
Hertfordshire
AL10 9SN
United Kingdom

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/12/776/024

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Fycompa 0.5 mg/ml

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC:
SN:
NN:
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Fycompa is and what it is used for
2. What you need to know before you take Fycompa
3. How to take Fycompa
4. Possible side effects
5. How to store Fycompa
6. Contents of the pack and other information

1. What Fycompa is and what it is used for

Fycompa contains a medicine called perampanel. It belongs to a group of medicines called anti epileptics. These medicines are used to treat epilepsy - where someone has repeated fits (seizures). It has been given to you by your doctor to reduce the number of fits that you have.

Fycompa is used in association with other antiepileptic drugs to treat certain forms of epilepsy in people aged 12 years and older.
- It is used to treat fits that affect one part of your brain (called a “partial seizure”).
- These partial seizures may or may not then be followed by a fit affecting all of your brain (called a “secondary generalisation”).
- It is also used to treat certain fits that affect all of your brain from the start (called “generalised seizures”) and cause convulsions or staring spells.

2. What you need to know before you take Fycompa

Do not take Fycompa if:
- you are allergic to perampanel or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before taking Fycompa if you have liver problems or moderate or severe kidney problems.
You should not take Fycompa if you have serious liver problems or moderate or serious kidney problems.
Before taking this medicine you should tell your doctor if you have a history of alcoholism or drug dependence.
- Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
- Fycompa may make you more likely to fall over, particularly if you are an older person; this might be due to your illness.
Fycompa may make you aggressive, angry or violent. It may also cause you to have unusual or extreme changes in behaviour or mood. If any of these happens, talk to your doctor or pharmacist.

A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.

If you experience any of the above after taking Fycompa (or you are not sure) talk to your doctor or pharmacist.

**Children**

Fycompa is not recommended for children aged under 12. The safety and effectiveness are not yet known in this age group.

**Other medicines and Fycompa**

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. Taking Fycompa with certain other medicines may cause side effects or affect how they work. Do not start or stop other medicines without talking to your doctor or pharmacist.

- Other anti-epileptic medicines, such as carbamazepine, oxcarbazepine, and phenytoin that are used to treat fits may affect Fycompa. Tell your doctor if you are taking or have recently taken these medicines as your dose may need to be adjusted.
- Felbamate (a medicine used to treat epilepsy) may also affect Fycompa. Tell your doctor if you are taking or have recently taken this medicine as your dose may need to be adjusted.
- Midazolam (a medicine used to stop prolonged, acute (sudden) convulsive seizures, for sedation and sleep problem) may be affected by Fycompa. Tell your doctor if you are taking midazolam as your dose may need to be adjusted.
- Some other medicines such as rifampicin (a medicine used to treat bacterial infections), hypericum (St. John’s Wort) (a medicine used to treat mild anxiety) and ketoconazole (a medicine used to treat fungal infections) may affect Fycompa. Tell your doctor if you are taking or have recently taken these medicines as your dose may need to be adjusted.
- Oral contraceptives (also called “hormonal contraceptives”).

Tell your doctor if you are taking hormonal contraceptives. Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective. You should use other forms of safe and effective contraception (such as a condom or coil) when taking Fycompa. You should continue doing this for one month after stopping treatment. Discuss with your doctor what may be appropriate contraception for you.

**Fycompa with alcohol**

Speak to your doctor before drinking alcohol. Be careful about consuming alcohol with epilepsy medicines including Fycompa.

- Drinking alcohol while taking Fycompa can make you less alert and affect your ability to drive or use tools or machines.
- Drinking alcohol while taking Fycompa can also make any feelings of anger, confusion or sadness worse.

**Pregnancy and breast-feeding**

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Do not stop treatment without first discussing it with your doctor.

- Fycompa is not recommended in pregnancy.
- You must use a reliable method of contraception to avoid becoming pregnant while you are being treated with Fycompa. You should continue doing this for one month after stopping treatment. Tell your doctor if you are taking hormonal contraceptives. Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective. You should use other forms of safe and effective contraception (such as a condom or coil) when taking Fycompa. You
should also do this for one month after stopping treatment. Discuss with your doctor what may be appropriate contraception for you.

It is not known whether the ingredients of Fycompa can pass into breast milk.
The doctor will weigh up the benefit and risks to your baby of taking Fycompa while you are breast-feeding.

**Driving and using machines**
Do not drive or use machines until you know how Fycompa affects you.

You must talk to your doctor about the effect of your epilepsy on driving and using machines.

- Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment. If this happens to you, do not drive or use any tools or machines.
- Drinking alcohol while taking Fycompa may make these effects worse.

**Fycompa contains lactose**

Fycompa contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

### 3. How to take Fycompa

Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

**How much to take**
The usual starting dose is 2 mg once a day before you go to bed.

- Your doctor may increase this in 2 mg steps to a maintenance dose between 4 mg and 12 mg - depending on your response.
- If you have mild or moderate liver problems, your dose should not be more than 8 mg each day and your dose increases should be at least 2 weeks apart.
- Don’t take more Fycompa than your doctor has recommended. It may take a few weeks to find the right dose of Fycompa for you.

**How to take**
Swallow the tablet whole with a glass of water. You can take Fycompa with or without food. Do not chew, crush or split the tablet. The tablets cannot be split accurately as there is no break line.

**If you take more Fycompa than you should**
If you have taken more Fycompa than you should contact your doctor straight away. You may experience confusion, agitation and aggressive behaviour.

**If you forget to take Fycompa**
- If you forget to take a tablet, wait until your next dose and then carry on as usual.
- Do not take a double dose to make up for a forgotten dose.
- If you have missed less than 7 days of treatment with Fycompa, continue taking your daily tablet as originally instructed by your doctor.
- If you have missed more than 7 days of treatment with Fycompa, talk to your doctor immediately.

**If you stop taking Fycompa**
Take Fycompa for as long as your doctor recommends. Do not stop unless your doctor advises you to.
Your doctor may reduce your dose slowly to avoid your fits (seizures) coming back or getting worse.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.

**Very common** (may affect more than 1 user in 10) are:
- feeling dizzy
- feeling sleepy (drowsiness or somnolence)

**Common** (may affect more than 1 user in 100) are:
- increased or decreased appetite, weight gain
- feeling aggressive, angry, irritable, anxious or confused
- difficulty with walking or other balance problems (ataxia, gait disturbance, balance disorder)
- slow speech (dysarthria)
- blurred vision or double vision (diplopia)
- spinning sensation (vertigo)
- feeling sick (nausea)
- back pain
- feeling very tired (fatigue)
- falling down.

**Uncommon** (may affect more than 1 user in 1000) are:
- thoughts about harming yourself or ending your own life (suicidal thoughts), tried to end your own life (attempted suicide)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Fycompa**

Keep out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of the month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. **Contents of the pack and other information**

**What Fycompa contains**
The active substance is perampanel. Each film-coated tablet contains 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg perampanel.

The other ingredients are:
Tablet core (2 mg and 4 mg tablets):
Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, magnesium stearate (E470b)

Tablet core (6 mg, 8 mg, 10 mg and 12 mg tablets)
Lactose monohydrate, low-substituted hydroxypropyl cellulose, povidone, microcrystalline cellulose, magnesium stearate (E470b)

Film coating (2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg tablets)
Hypromellose 2910, talc, Macrogol 8000, titanium dioxide (E171), colourants*

*The colourants are:
2 mg tablet: Ferric Oxide, Yellow (E172), Ferric Oxide, Red (E172)
4 mg tablet: Ferric Oxide, Red (E172)
6 mg tablet: Ferric Oxide, Red (E172)
8 mg tablet: Ferric Oxide, Red (E172), Ferric Oxide, Black (E172)
10 mg tablet: Ferric Oxide, Yellow (E172), FD&C Blue #2 Indigo carmine aluminium lake (E132)
12 mg tablet: FD&C Blue #2 Indigo carmine aluminium lake (E132)

**What Fycompa looks like and contents of the pack**
All strengths of Fycompa are round, biconvex film-coated tablets
2 mg: orange, marked with E275 on one side and 2 on other side
4 mg: red, marked with E277 on one side and 4 on other side
6 mg: pink, marked with E294 on one side and 6 on other side
8 mg: purple, marked with E295 on one side and 8 on other side
10 mg: green, marked with E296 on one side and 10 on other side
12 mg: blue, marked with E297 on one side and 12 on other side

Fycompa is available in packs of:
2 mg tablet – pack of 7, 28 and 98
4 mg, 6 mg, 8 mg, 10 mg, 12 mg tablets – packs of 7, 28, 84 and 98

Not all pack sizes may be marketed

**Marketing Authorisation Holder**
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom
e-mail: EUmedinfo@eisai.net

**Manufacturer**
Eisai Manufacturing Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58

**Luxembourg/Luxemburg**
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58
(Belgique/Belgien)
<table>
<thead>
<tr>
<th>страна</th>
<th>организация</th>
<th>номер телефона</th>
<th>комментарий</th>
</tr>
</thead>
<tbody>
<tr>
<td>България</td>
<td>Eisai Ltd.</td>
<td>+ 44 (0)208 600 1400</td>
<td>(Обединено кралство)</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Eisai Ltd.</td>
<td>+ 44 (0)208 600 1400</td>
<td>Egyesült Királyság</td>
</tr>
<tr>
<td>Česká republika</td>
<td>Eisai GesmbH organizační složka</td>
<td>+ 420 242 485 839</td>
<td></td>
</tr>
<tr>
<td>Malta</td>
<td>Associated Drug Co. Ltd</td>
<td>+ 356 2277 8000</td>
<td></td>
</tr>
<tr>
<td>Danmark</td>
<td>Eisai AB</td>
<td>+ 46 (0) 8 501 01 600</td>
<td>(Сverige)</td>
</tr>
<tr>
<td>Nederland</td>
<td>Eisai B.V.</td>
<td>+ 31 (0) 900 575 3340</td>
<td></td>
</tr>
<tr>
<td>Deutschland</td>
<td>Eisai GmbH</td>
<td>+ 49 (0) 69 66 58 50</td>
<td></td>
</tr>
<tr>
<td>Österreich</td>
<td>Eisai GesmbH</td>
<td>+ 43 (0) 1 535 1980-0</td>
<td></td>
</tr>
<tr>
<td>Elládóú</td>
<td>Arriani Pharmaceuticals S.A.</td>
<td>+ 30 210 668 3000</td>
<td></td>
</tr>
<tr>
<td>Polska</td>
<td>Eisai Ltd.</td>
<td>+ 44 (0)208 600 1400</td>
<td>(Вielka Britania)</td>
</tr>
<tr>
<td>España</td>
<td>Eisai Farmacéutica, S.A.</td>
<td>+ (34) 91 455 94 55</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>Eisai SAS</td>
<td>+ (33) 1 47 67 00 05</td>
<td></td>
</tr>
<tr>
<td>Hrvatska</td>
<td>Eisai Ltd.</td>
<td>+ 44 (0)208 600 1400</td>
<td>(Вelika Britanija)</td>
</tr>
<tr>
<td>Slovenija</td>
<td>Eisai Ltd.</td>
<td>+ 44 (0)208 600 1400</td>
<td>(Вelika Britanija)</td>
</tr>
<tr>
<td>Islând</td>
<td>Eisai AB</td>
<td>+ 46 (0)8 501 01 600</td>
<td>(Svíþjóð)</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Eisai AB</td>
<td>+ 46 (0) 8 501 01 600</td>
<td>(Ruotsi)</td>
</tr>
</tbody>
</table>
This leaflet was last revised in {MM/YYYY}

Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:
1. What Fycompa is and what it is used for
2. What you need to know before you take Fycompa
3. How to take Fycompa
4. Possible side effects
5. How to store Fycompa
6. Contents of the pack and other information

1. What Fycompa is and what it is used for

Fycompa contains a medicine called perampanel. It belongs to a group of medicines called anti-epileptics. These medicines are used to treat epilepsy - where someone has repeated fits (seizures). It has been given to you by your doctor to reduce the number of fits that you have.

Fycompa is used in association with other antiepileptic drugs to treat certain forms of epilepsy in people aged 12 years and older.
- It is used to treat fits that affect one part of your brain (called a “partial seizure”).
- These partial seizures may or may not then be followed by a fit affecting all of your brain (called a “secondary generalisation”).
- It is also used to treat certain fits that affect all of your brain from the start (called “generalised seizures”) and cause convulsions or staring spells.

2. What you need to know before you take Fycompa

Do not take Fycompa if:
- you are allergic to perampanel or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Talk to your doctor or pharmacist before taking Fycompa if you have liver problems or moderate or severe kidney problems.
You should not take Fycompa if you have serious liver problems or moderate or serious kidney problems.
Before taking this medicine you should tell your doctor if you have a history of alcoholism or drug dependence.

- Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment.
- Fycompa may make you more likely to fall over, particularly if you are an older person; this might be due to your illness.
Fycompa may make you aggressive, angry or violent. It may also cause you to have unusual or extreme changes in behaviour or mood. If any of these happens, talk to your doctor or pharmacist.

A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.

If you experience any of the above after taking Fycompa (or you are not sure) talk to your doctor or pharmacist.

Children
Fycompa is not recommended for children aged under 12. The safety and effectiveness are not yet known in this age group.

Other medicines and Fycompa
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines. Taking Fycompa with certain other medicines may cause side effects or affect how they work. Do not start or stop other medicines without talking to your doctor or pharmacist.

- Other anti-epileptic medicines, such as carbamazepine, oxcarbazepine, and phenytoin that are used to treat fits may affect Fycompa. Tell your doctor if you are taking or have recently taken these medicines as your dose may need to be adjusted.
- Felbamate (a medicine used to treat epilepsy) may also affect Fycompa. Tell your doctor if you are taking or have recently taken this medicine as your dose may need to be adjusted.
- Midazolam (a medicine used to stop prolonged, acute (sudden) convulsive seizures, for sedation and sleep problem) may be affected by Fycompa. Tell your doctor if you are taking midazolam as your dose may need to be adjusted.
- Some other medicines such as rifampicin (a medicine used to treat bacterial infections), hypericum (St. John’s Wort) (a medicine used to treat mild anxiety) and ketoconazole (a medicine used to treat fungal infections) may affect Fycompa. Tell your doctor if you are taking or have recently taken these medicines as your dose may need to be adjusted.
- Oral contraceptives (also called “hormonal contraceptives”).

Tell your doctor if you are taking hormonal contraceptives. Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective. You should use other forms of safe and effective contraception (such as a condom or coil) when taking Fycompa. You should continue doing this for one month after stopping treatment. Discuss with your doctor what may be appropriate contraception for you.

Fycompa with alcohol
Speak to your doctor before drinking alcohol. Be careful about consuming alcohol with epilepsy medicines including Fycompa.

- Drinking alcohol while taking Fycompa can make you less alert and affect your ability to drive or use tools or machines.
- Drinking alcohol while taking Fycompa can also make any feelings of anger, confusion or sadness worse.

Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. Do not stop treatment without first discussing it with your doctor.

- Fycompa is not recommended in pregnancy.
- You must use a reliable method of contraception to avoid becoming pregnant while you are being treated with Fycompa. You should continue doing this for one month after stopping treatment. Tell your doctor if you are taking hormonal contraceptives. Fycompa may make certain hormonal contraceptives such as levonorgestrel less effective. You should use other forms of safe and effective contraception (such as a condom or coil) when taking Fycompa. You
should also do this for one month after stopping treatment. Discuss with your doctor what may be appropriate contraception for you.

It is not known whether the ingredients of Fycompa can pass into breast milk. The doctor will weigh up the benefit and risks to your baby of taking Fycompa while you are breast-feeding.

**Driving and using machines**
Do not drive or use machines until you know how Fycompa affects you. You must talk to your doctor about the effect of your epilepsy on driving and using machines.
- Fycompa may make you feel dizzy or sleepy, particularly at the beginning of treatment. If this happens to you, do not drive or use any tools or machines.
- Drinking alcohol while taking Fycompa may make these effects worse.

**Fycompa contains sorbitol**
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Fycompa.

Taking Fycompa with other anti-epileptic medicine, which contains sorbitol, may affect how much they work. Tell your doctor or pharmacist if you are taking any other anti-epileptic medicine(s) with sorbitol.

### 3. How to use Fycompa

Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

**How much to take**
The usual starting dose is 2 mg (4 ml) once a day before you go to bed.
- Your doctor may increase this in 2 mg (4 ml) steps to a maintenance dose between 4 mg (8 ml) and 12 mg (24 ml) depending on your response.
- If you have mild or moderate liver problems, your dose should not be more than 8 mg each day and your dose increases should be at least 2 weeks apart.
- Don’t take more Fycompa than your doctor has recommended. It may take a few weeks to find the right dose of Fycompa for you.

**How to take**
Fycompa is for oral use. You can take Fycompa with or without food and should always take it the same way. For example, if you decide to take Fycompa with food, always take it that way.

For dosing please use the oral syringe and adaptor provided.

Instructions on how to use the oral syringe and adaptor are provided below:

1. Shake for at least 5 seconds before use.
2. Push down and turn cap to open bottle.
3. Insert adaptor into the neck of the bottle until a tight seal is made.
5. Insert the oral syringe into the opening of the adaptor as far as possible.
6. Turn upside down and withdraw the prescribed amount of Fycompa from the bottle.
7. Turn upright and remove the oral syringe.
8. Leave the adaptor in place and replace cap on bottle. Wash the oral syringe with clean water and dry thoroughly.

**If you take more Fycompa than you should**
If you have taken more Fycompa than you should contact your doctor straight away. You may experience confusion, agitation and aggressive behaviour.

**If you forget to take Fycompa**
- If you forget to take Fycompa, wait until your next dose and then carry on as usual.
- Do not take a double dose to make up for a forgotten dose.
- If you have missed less than 7 days of treatment with Fycompa, continue taking your daily dose as originally instructed by your doctor.
- If you have missed more than 7 days of treatment with Fycompa, talk to your doctor immediately.

**If you stop taking Fycompa**
Take Fycompa for as long as your doctor recommends. Do not stop unless your doctor advises you to. Your doctor may reduce your dose slowly to avoid your fits (seizures) coming back or getting worse. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

A small number of people being treated with anti-epileptics have had thoughts of harming or killing themselves. If at any time you have these thoughts, contact your doctor straight away.

**Very common** (may affect more than 1 user in 10) are:
- feeling dizzy
- feeling sleepy (drowsiness or somnolence)

**Common** (may affect more than 1 user in 100) are:
- increased or decreased appetite, weight gain
- feeling aggressive, angry, irritable, anxious or confused
- difficulty with walking or other balance problems (ataxia, gait disturbance, balance disorder)
- slow speech (dysarthria)
- blurred vision or double vision (diplopia)
- spinning sensation (vertigo)
- feeling sick (nausea)
- back pain
- feeling very tired (fatigue)
- falling down.

**Uncommon** (may affect more than 1 user in 1000) are:
- thoughts about harming yourself or ending your own life (suicidal thoughts), tried to end your own life (attempted suicide)

**Reporting of side effects**
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. **How to store Fycompa**

Keep out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle label and carton. The expiry date refers to the last day of the month.

This medicinal product does not require any special storage conditions.

If you have any suspension left in the bottle more than 90 days after it was first opened, you should not use it.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. **Contents of the pack and other information**

**What Fycompa contains**
- The active substance is perampanel. Each millilitre contains 0.5 mg of perampanel.
- The other ingredients are sorbitol (E420) liquid (crystallising), microcrystalline cellulose (E460), carmellose sodium (E466), poloxamer 188, simethicone emulsion 30% (containing purified water, silicone oil, polysorbate 65, methylcellulose, silica gel, macrogol stearate, sorbic acid, benzoic acid and sulfuric acid), citric acid, anhydrous (E330), sodium benzoate (E211) and purified water.

**What Fycompa looks like and contents of the pack**
Fycompa 0.5 mg/ml oral suspension is a white to off-white suspension. It comes in a bottle of 340 ml with 2 graduated oral syringes and an LDPE press-in bottle adapter (PIBA).

**Marketing Authorisation Holder**
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom
e-mail: EUmedinfo@eisai.net

**Manufacturer**
Eisai Manufacturing Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**Belgien/Belgique/België**
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58

**Luxembourg/Luxemburg**
Eisai SA/NV
Tél/Tel: +32 (0)800 158 58
(Belgique/Belgien)

**България**
Eisai Ltd.
Тел.: + 44 (0)208 600 1400
(Обединено кралство)

**Magyarország**
Eisai Ltd.
Tel.: + 44 (0)208 600 1400
Egyesült Királyság
Česká republika
Eisai GesmbH organizační složka
Tel.: + 420 242 485 839

Malta
Associated Drug Co. Ltd
Tel: + 356 2277 8000

Danmark
Eisai AB
Tlf: + 46 (0) 8 501 01 600
(Sverige)

Nederland
Eisai B.V.
Tél/Tel: + 31 (0) 900 575 3340

Deutschland
Eisai GmbH
Tel: + 49 (0) 69 66 58 50

Østerrike
Eisai GesmbH
Tel: + 43 (0) 1 535 1980-0

Eesti
Eisai Ltd.
Tel: + 44 (0) 208 600 1400
(Uhendkuningriik)

Polska
Eisai Ltd.
Tel.: + 44 (0) 208 600 1400
(Wielka Brytania)

España
Eisai Farmacéutica, S.A.
Tel: + (34) 91 455 94 55

Portugal
Eisai Farmacêutica, Unipessoal Lda
Tel: + 351 214 875 540

France
Eisai SAS
Tél: + (33) 1 47 67 00 05

România
Eisai Ltd.
Tel: + 44 (0) 208 600 1400
(Marea Britanie)

Hrvatska
Eisai Ltd.
Tel: + 44 (0) 208 600 1400
(Velika Britanija)

Slovenija
Eisai Ltd.
Tel: + 44 (0) 208 600 1400
(Velika Britanija)

Ireland
Eisai Ltd.
Tel: + 44 (0) 208 600 1400
(United Kingdom)

Slovenská republika
Eisai GesmbH organizační složka
Tel.: + 420 242 485 839
(Česká republika)

Ísland
Eisai AB
Sími: + 46 (0) 8 501 01 600
(Svíþjóð)

Suomi/Finland
Eisai AB
Puh/Tel: + 46 (0) 8 501 01 600
(Ruotsi)

Italia
Eisai S.r.l.
Tel: + 39 02 5181401

Sverige
Eisai AB
Tel: + 46 (0) 8 501 01 600
This leaflet was last revised in {MM/YYYY}

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu